Healthcare

Eli Lilly’s Foundayo will be available to patients through the drugmaker’s online pharmacy.

The stock hasn't performed well since Barron’s picked it.

United Therapeutics stock entered Monday up 7% on the year, but moved higher on the Tyvaso drug trial results.

Lilly will obtain exclusive rights to sell treatments discovered using InSilico’s Pharma.AI model.

The agreement would cover the company’s Caremark pharmacy benefit manager unit, which has denied wrongdoing.

We looked for promising names in materials and healthcare, and found some investments that should thrive in today’s economy.

Fallout from the Middle East conflict is rippling through the global economy—and growing worse the longer it lasts.

Investors have ignored healthcare as they have tried to capture earnings momentum in AI-related semiconductor stocks.

One feature will allow Fitbit users to share their medical records with the app’s AI-powered health coach.

Nvidia stock pares back gains following a solid jump on the first day of the chip maker’s annual developer conference.

Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.

Adobe shares fell following the resignation of CEO Shantanu Narayen, who served in the role for nearly two decades.

The Iran war won’t go on forever. And when it ends, the stock market could resume its winning ways.

The energy shock has hit markets in Europe and Asia, but their growth drivers are intact. Where to find bargains.

Insights from hedge fund manager Guy Spier in the wake of his terminal disease diagnosis.

Aetna paid a $117.7 million settlement over allegations it submitted inaccurate diagnosis code to inflate Medicare payments.

Drugstore stocks, a car company and consumer stocks with low price-to-earnings ratios are all good bets.

Shares in electric-vehicle makers Rivian Automotive and NIO rise following an upgrade and strong earnings, respectively.

The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.

Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.

Centene’s CEO says the company expects to see continued contraction in its Affordable Care Act marketplace.

The German biotech provides a weak full-year outlook and announces the exit of its co-founders.

Hims & Hers Health rallies after Novo Nordisk agrees to sell popular weight-loss drugs on its platform.

Novo Nordisk has agreed to sell its weight-loss injectables and its Wegovy pill on Hims’ platform.